Valproic Acid for the Treatment of Significant Hemorrhage
Award Notice Posted
- Solicitation number
- W81XWH20VPA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Awarded
- to Westat, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- W81XWH20C0122 Federal contract award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- USA
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice from the Department of the Army Medical Command announced a sole source contract award to Westat, Inc. valued at $13.2 million. The contract is for Westat to serve as the investigational new drug sponsor to manage Good Clinical Practice compliant clinical trials for using valproic acid to treat patients with significant hemorrhage. As the holder of the investigational new drug application for this indication and having completed prerequisite pre-clinical studies and meetings with the Food and Drug Administration under a prior contract, awarding this follow-on contract to Westat will help obtain regulatory approval and field this critical treatment option in a timely manner without costly duplication of efforts.
Notice text
Refer to attachment/JA.
Awarded contract W81XWH20C0122 to WESTAT, INC. for 14139572.78 on 2020-09-24.
Files
| File | Type | Posted |
|---|---|---|
| JA_W81XWH20C0122_Redacted_Final.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Valproic Acid for the Treatment of Significant Hemorrhage | Limited / Sole Source Justification | |
| Valproic Acid for the Treatment of Significant Hemorrhage | Special Notice | |
| Valproic Acid for the Treatment of Significant Hemorrhage | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity